APHB AmpliPhi Biosciences Corporation

1.02
-0.06  -6%
Previous Close 1.08
Open 1.06
Price To book 0.90
Market Cap 8924033
Shares 8,749,052
Volume 364,435
Short Ratio 6.76
Av. Daily Volume 382,327

SEC filingsSee all SEC filings

  1. 8-K - Current report 171094106
  2. 8-K - Current report 171079181
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030262
  4. 8-K - Current report 171030126
  5. DEF 14A - Other definitive proxy statements 17978646

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
AB-SA01
Chronic rhinosinusitis (CRS)

Latest News

  1. AmpliPhi Biosciences’ CEO to Moderate Panel Discussion at Upcoming Anti-Infectives Rx Conference
  2. AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus
  3. AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive
  4. AmpliPhi Biosciences to Present at Rodman & Renshaw 19th Annual Global Investment Conference
  5. APHB: Patient Treated Under Expanded Access Protocol With AB-PA01
  6. AmpliPhi Biosciences Announces Publication of Bacteriophage Case Study for Life-Threatening Antibiotic-Resistant Infection
  7. AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
  8. AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights
  9. Investor Network: AmpliPhi BioSciences Corporation to Host Earnings Call
  10. AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update Conference Call on August 14
  11. AmpliPhi Biosciences Novel Approach to Treating Bacterial Infection
  12. AmpliPhi Biosciences to Present at Bacteriophage Therapy Workshop Sponsored by the FDA and NIH
  13. APHB: New CEO to Lead New Strategic Focus
  14. AmpliPhi Biosciences Announces Presentation and Panel Participation at BIO International Convention
  15. AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer
  16. AmpliPhi Biosciences to Present at 7th Annual LD Micro Invitational Conference on June 6
  17. AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
  18. APHB: Changing Focus to Developing Personalized Phage Therapies…
  19. AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights
  20. AmpliPhi Biosciences to Hold Business Update Conference Call on May 15

SEC Filings

  1. 8-K - Current report 171094106
  2. 8-K - Current report 171079181
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030262
  4. 8-K - Current report 171030126
  5. DEF 14A - Other definitive proxy statements 17978646
  6. PRE 14A - Other preliminary proxy statements 17965932
  7. 8-K - Current report 17942793
  8. 8-K - Current report 17894457
  9. 8-K - Current report 17891562
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17844253